Innovative Gene Therapy iECURE focuses on mutation-agnostic, in vivo gene insertion therapies targeting devastating liver disorders, presenting an opportunity to collaborate on cutting-edge genetic medicine solutions and expand your portfolio in advanced biotech treatments.

Growing Clinical Pipeline With ECUR-506 in Phase 1/2 clinical trials for OTC deficiency and recent data showcasing potential for functional enzyme restoration, there is a clear pipeline with significant market and treatment potential that can benefit from strategic partnerships and supply chain support.

Regulatory Milestones Recognition through Fast Track designation from the FDA underscores the company's progress toward market approval, creating opportunities to support their regulatory navigation, commercialization strategies, and market entry solutions.

Strong Industry Engagement Active participation in major gene and clinical genetics conferences indicates high visibility within the biotech community, providing avenues for partnership development, research collaboration, and investment alignment in innovative genetic therapies.

Funding & Leadership With solid funding of 65 million dollars and experienced leadership including notable board members and medical officers, iECURE is positioned for accelerated growth, making it a promising partner for investors, suppliers, and technology providers seeking strategic alliances in biotech innovation.